Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy

OBJECTIVE: To compare changes over 48 weeks in bone mineral density (BMD) between participants randomized to lopinavir/ritonavir (LPV/r) + raltegravir (RAL) or LPV/r + 2–3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs) as second line therapy. DESIGN: 48-week open-label sub-study o...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Allison, Moore, Cecilia, Mallon, Patrick W.G., Hoy, Jennifer, Emery, Sean, Belloso, Waldo, Phanuphak, Praphan, Ferret, Samuel, Cooper, David A., Boyd, Mark A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2013
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815006/
https://www.ncbi.nlm.nih.gov/pubmed/23921615
http://dx.doi.org/10.1097/01.aids.0000432534.47217.b4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815006/
https://www.ncbi.nlm.nih.gov/pubmed/23921615
http://dx.doi.org/10.1097/01.aids.0000432534.47217.b4

Ejemplares similares